A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is primarily to investigate the safety and tolerability of repeated
subcutaneous injections of MT203 in patients with mild to moderate rheumatoid arthritis.
Furthermore, the amount of MT203 in the blood will be measured and it will be investigated
how the body responds to MT203 treatment and if MT203 is effective in the treatment of
rheumatoid arthritis.